Aegerion Pharmaceuticals (AEGR -4.4%) is getting no love from investors this morning despite...

|About: Aegerion Pharmaceuticals (AEGR)|By:, SA News Editor

Aegerion Pharmaceuticals (AEGR -4.4%) is getting no love from investors this morning despite getting FDA approval for its first approved product, Juxtapid, a treatment for Hypercholesterolemia, which is an inherited disorder that can result in high cholesterol. However, the FDA is requiring a black box warning regarding the drug's liver toxicity, and the company also must certify doctors and receive preauthorization from insurers before patients can receive the drug.